Joint Strategy. In the event that the manufacture, use or sale of a Program Product based upon or incorporating the Licensed Validated Compound becomes the subject of a claim of infringement of a patent, copyright or other proprietary right anywhere in the world, and without regard to which Party is charged with said infringement, or the venue of such claim, the Parties [ * ] shall promptly confer to discuss the claim. [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
Appears in 2 contracts
Sources: Collaboration Agreement (Tularik Inc), Collaboration Agreement (Tularik Inc)